Latest news with #hemodialysis
Yahoo
13-05-2025
- Business
- Yahoo
Rockwell Medical Inc (RMTI) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...
Net Sales: $18.9 million, a 17% decrease from $22.7 million in Q1 2024. Gross Profit: $3 million, consistent with the same period in 2024. Gross Margin: 16%, up from 14% in Q1 2024. Net Loss: $1.5 million, improved from a net loss of $1.7 million in Q1 2024. Adjusted EBITDA: Negative $400,000. Cash, Cash Equivalents, and Investments: $17.3 million as of March 31, 2025, down from $21.6 million at December 31, 2024. Projected 2025 Net Sales Guidance: Between $65 million and $70 million. Projected 2025 Gross Margin Guidance: Between 16% and 18%. Projected 2025 Adjusted EBITDA Guidance: Between negative $500,000 and positive $500,000. Warning! GuruFocus has detected 3 Warning Signs with RMTI. Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Rockwell Medical Inc (NASDAQ:RMTI) successfully diversified its customer base by signing new contracts with leading regional, national, and global hemodialysis providers. The company maintained its gross margin within the guidance range for the year, demonstrating effective cost management. Rockwell Medical Inc (NASDAQ:RMTI) launched a new single-use bicarbonate cartridge technology, expanding its product portfolio and addressing a growing market segment. The company is actively pursuing business development opportunities that could strengthen its position in the renal market and provide access to new markets. Rockwell Medical Inc (NASDAQ:RMTI) reiterated its projected guidance for 2025, indicating confidence in achieving net sales between $65 million and $70 million. Net sales for the first quarter decreased by 17% compared to the same period in 2024, primarily due to the largest customer transitioning to another supplier. The company experienced a net loss of $1.5 million for Q1 2025, although this was an improvement over the previous year's loss. Adjusted EBITDA for Q1 2025 was negative $400,000, impacted by seasonal items associated with payroll tax and other expenses. Cash, cash equivalents, and investments decreased from $21.6 million at the end of 2024 to $17.3 million at the end of Q1 2025. The ongoing negotiations with the largest customer may result in a scaled-down contractual commitment, potentially impacting future revenue. Q: Can you provide an update on the negotiations with your largest historical customer and the potential scenarios that could arise from these discussions? Also, what is the expected revenue cadence for the remainder of 2025? A: Discussions with our largest customer are ongoing to maintain some level of service, likely at a smaller scale than before. We aim to establish a long-term arrangement to supply them, including replenishing their safety stock. Regarding revenue, we are in the process of acquiring new customers, which could be significant. We are confident in our guidance and expect Q2 to be the low point for the year, with improvements thereafter. Q: Could you comment on the at-home dialysis market and your specific product offerings in this area? A: The at-home dialysis market is progressing as expected and is growing. Our product offering for this market is gaining traction, and we anticipate increased sales in the second half of the year. This product not only improves patient experience but also offers higher margins for us. Q: Can you provide more information on your international market expansion, particularly on the West Coast? A: We are expanding primarily in Latin America, which presents significant opportunities. For the West Coast of the U.S., we see potential as it is largely supported by one manufacturer. We are considering establishing a facility there to capitalize on this opportunity, but no final decisions have been made yet. Q: How do you plan to mitigate the revenue loss from your largest customer transitioning to another supplier? A: We believe there are enough opportunities among small independent dialysis providers and within our existing footprint to replace a significant portion of the lost revenue. Our focus is on expanding our customer base domestically and internationally, particularly in Latin America. Q: Is the revenue guidance you reaffirmed today based on your current customer base, and could new customers provide potential upside? A: Yes, the guidance is based on our current customer base. Any new customers acquired during the year would provide potential upside to our revenue projections. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Health Line
12-05-2025
- Health
- Health Line
Choosing Between Hemodialysis and Peritoneal Dialysis
For most people, hemodialysis and peritoneal dialysis are equally effective treatments for end stage renal disease. Factors such as your health, preferences, and the costs may influence your final decision. When kidney disease progresses to the point when your kidneys can no longer function effectively (also known as end stage renal disease, or ESRD), a doctor may recommend dialysis. What a lot of people don't know is that you can choose between different types of dialysis. Hemodialysis is the most common dialysis treatment. But in a 2024 survey, more than half of respondents reported having insufficient knowledge about peritoneal dialysis, a less common but equally effective dialysis option. Keep reading to learn more about the differences between hemodialysis and peritoneal dialysis, the pros and cons of each, and what to consider when making a decision. What does hemodialysis involve? Hemodialysis uses a machine called a dialyzer to filter your blood outside of your body. The dialyzer then returns the filtered blood to your body. People sometimes call a dialyzer an 'artificial kidney' since it does some of the work that healthy kidneys do. Because blood needs to leave and reenter your body, hemodialysis requires an access point. You typically need to undergo a surgical procedure for a doctor to create an access point, most often an arteriovenous (AV) fistula or AV graft, in your arm. If you only need temporary access, they may place a central venous catheter instead. People typically go to a dialysis center for 3- to 4-hour sessions three times a week. However, you can also opt for home hemodialysis, which allows for a more flexible schedule. While on dialysis, you'll also need to adjust your diet, including eating more protein and limiting salt and fluids. A renal dietitian will work with you to ensure you're meeting your nutritional needs. Hemodialysis can also cause side effects like itchy skin and muscle cramps. A potential complication is hypotension (low blood pressure). Some complications are related to the dialyzer itself, such as allergic reactions. Pros of hemodialysis life-preserving treatment you can sustain for years easier if you prefer to have a healthcare professional perform sessions can be done at home if preferred Cons of hemodialysis potentially increased time burden for travel less flexibility in scheduling if you go to a dialysis center challenging for people who have a fear of needles may need to dedicate space in your home for the machine and supplies if you choose home dialysis may require a dialysis partner if you choose home dialysis What does peritoneal dialysis involve? Instead of a dialyzer, peritoneal dialysis uses the lining of your abdomen as a filter. This means filtration takes place inside your body. You'll still require surgery before starting peritoneal dialysis, but instead of creating a fistula or graft in your arm, the surgeon places a catheter in your abdomen. The filtering process involves passing a sterile cleansing fluid into the catheter over 30 to 40 minutes. You then put a cap on the catheter and go about your day. After 4 to 6 hours, you can remove the cap and discard the solution. You do this three to five times a day. People on peritoneal dialysis still need to alter their diet, but they may be able to eat more than people on hemodialysis. Peritoneal dialysis also causes different side effects from hemodialysis, like weight gain and high blood sugar. However, some people may be able to avoid this problem by using nonglucose-based solutions, like icodextrin. The most significant complications are hernia and peritonitis, a bacterial infection of the abdominal lining. Proper technique and care of the catheter equipment can help prevent this. Continuous vs. automated peritoneal dialysis You can choose from one of two types of peritoneal dialysis. The procedure described above — continuous ambulatory peritoneal dialysis (CAPD) — doesn't require a machine. You may also opt for automated peritoneal dialysis (APD), which uses a machine to perform the exchanges while you sleep. People who elect peritoneal dialysis often undergo a peritoneal equilibrium test to help determine how often they need to perform exchanges and whether CAPD or APD may be a better fit. Pros of peritoneal dialysis typically as effective as hemodialysis greater flexibility in when and where you can perform dialysis doesn't require needles CAPD doesn't require a machine may be able to eat more than with hemodialysis can control fluid intake more regularly usually cheaper than hemodialysis may take less time overall when you account for appointments, travel, etc. Cons of peritoneal dialysis requires training to perform dialysis on your own performed every day, so you don't have days off more prone to user error requires ongoing care of catheter equipment need to dedicate storage space at home for supplies and fluids challenging for people with severe obesity or previous abdominal surgeries What are the key differences between hemodialysis and peritoneal dialysis? Some of the key differences between hemodialysis and peritoneal dialysis are as follows: Hemodialysis Peritoneal dialysis How it works a machine filters your blood your abdominal lining filters your blood Access point AV fistula, AV graft, or catheter for vascular access in your arm catheter in your abdomen Location dialysis center or home home Frequency and duration • in a center: 3 times a week for 3 to 4 hours • at home: flexible, but 3 to 7 times a week for 2 to 5 hours • CAPD: varies, depending on the results of a peritoneal equilibrium test • APD: overnight Side effects and risks • fatigue • itchy skin • muscle cramps • low blood pressure • blood loss • blood clots • infections • dialyzer reactions • fatigue • high blood sugar • weight gain • hernia • peritonitis • blood clots Dietary guidelines • limit sodium, potassium, and phosphorus • limit fluid intake • increase protein same as for hemodialysis but may have fewer restrictions What factors should you consider when choosing between hemodialysis and peritoneal dialysis? For most people, choosing the type of dialysis may come down to personal preference and what suits your lifestyle best. You may need to consider your: life and work schedule social support network ability to travel comfort level with performing the procedure on your own home situation and ability to safely keep equipment and supplies financial resources Even after you make your choice, you can still change it later. You can't undergo hemodialysis if a doctor can't securely access a vein. Some medical conditions may also prevent you from choosing a specific type of dialysis. You likely can't undergo hemodialysis if you have: a bleeding disorder heart failure fear of needles Likewise, a doctor won't recommend peritoneal dialysis if you have: an uncorrected hernia in your abdominal wall a pleuroperitoneal shunt, which is a medical device that relieves fluid buildup in the pleural space scar tissue in your abdomen from a previous surgery Which is more effective: Hemodialysis or peritoneal dialysis? Although hemodialysis is much more common than peritoneal dialysis, both are equally effective. A 2018 study concluded that the two techniques were comparable in prolonging survival. A 2023 study even found that peritoneal dialysis may be more effective in: maintaining stable blood pressure and heart rate reducing blood pressure clearing molecules like urea and albumin from the blood protecting residual kidney function However, the type of dialysis that will be most effective for you will depend on your specific health situation. How much do hemodialysis and peritoneal dialysis cost? The amount you pay for a dialysis session depends on whether you have insurance, the type of insurance, and what your insurance covers. Most people who need dialysis qualify for Medicare, regardless of age. Medicare covers 80% of treatment costs for either hemodialysis or peritoneal dialysis. Your Medicare coverage typically starts on the first day of the fourth month of dialysis but can be backdated to the first month if you choose home dialysis and meet specific conditions.
Associated Press
12-05-2025
- Business
- Associated Press
Rockwell Medical Announces First Quarter 2025 Results
WIXOM, Mich.--(BUSINESS WIRE)--May 12, 2025-- Rockwell Medical, Inc. (the 'Company') (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. 'During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis providers and health systems. We remain a preferred provider as a result of our continued reliability, high-quality products, and customer-centric approach,' said MarkStrobeck, Ph.D., Rockwell Medical's President and CEO. 'Additionally, we continued to consolidate and further automate our manufacturing operations to reduce expenses and sustain our gross margin despite our largest customer moving away from Rockwell Medical. We look forward to sharing more updates in the months ahead.' FIRST QUARTER 2025 FINANCIAL HIGHLIGHTS FIRST QUARTER 2025 OPERATING HIGHLIGHTS GUIDANCE Rockwell confirms its 2025 annual guidance as follows: CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: Speakers: Format: Discussion of first quarter 2025 financial and operational results followed by Q&A. NON-GAAP FINANCIAL MEASURES To supplement Rockwell Medical's unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America ('GAAP'), this press release also includes references to adjusted EBITDA, a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual or not representative of underlying trends of our business, including but not limited to one-time severance costs, deferred revenue and inventory reserve amounts, if applicable for the periods presented. The Company has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to adjusted EBITDA. In addition, this press release includes a reference to adjusted EPS, a non-GAAP financial measure that is defined as adjusted EBITDA divided by the weighted average number of shares outstanding. The Company has also provided a reconciliation to EPS, or net income divided by the weighted average number of shares outstanding, which is the most directly comparable GAAP financial measure. Each of these adjusted measures is a non-GAAP financial measure. The Company has provided reconciliations to the GAAP measures at the end of this press release. Adjusted EBITDA and adjusted EPS are key measures used by Rockwell Medical to understand and evaluate operating performance and trends, to prepare and approve its annual budget, and to develop short- and long-term operating plans. The Company provides adjusted EBITDA because it believes the metric is helpful in highlighting trends in its operating results because it excludes items that are not indicative of Rockwell Medical's core operating performance. In particular, the Company believes that the exclusion of the items eliminated in calculating adjusted EBITDA provide useful measures for period-to-period comparisons of Rockwell Medical's business. This is also true for adjusted EPS, which is derived from adjusted EBITDA. Adjusted EBITDA and adjusted EPS should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of adjusted EBITDA and adjusted EPS as tools for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than the most directly comparable financial measures calculated in accordance with GAAP. When evaluating the Company's performance, you should consider adjusted EBITDA and adjusted EPS alongside other financial performance measures, including net loss, EPS and other GAAP results. ABOUT ROCKWELL MEDICAL Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work ® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & Production TM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions TM. For more information, visit FORWARD-LOOKING STATEMENTS Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as, 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'could,' 'can,' 'would,' 'develop,' 'plan,' 'potential,' 'predict,' 'forecast,' 'project,' 'intend,' 'look forward to,' 'remain confident,' 'feel confident,' 'guidance,' or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include (without limitation) statements regarding: expectations related to expenses for 2025 and annual guidance on net sales, gross margin and adjusted EBITDA. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include but are not limited to those risks more fully discussed in the 'Risk Factors' section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any subsequent reports filed with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law. Financial Tables Follow View source version on CONTACT: Heather R. Hunter SVP, Chief Corporate Affairs Officer (248) 432-1362 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN INDUSTRY KEYWORD: NURSING MEDICAL SUPPLIES MANUFACTURING DIABETES HEALTH PHARMACEUTICAL OTHER SCIENCE MEDICAL DEVICES OTHER MANUFACTURING HOSPITALS SCIENCE SOURCE: Rockwell Medical Copyright Business Wire 2025. PUB: 05/12/2025 06:00 AM/DISC: 05/12/2025 05:59 AM
